Vaxcyte Inc (PCVX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $10.03B
Last updated: Nov 17, 2026 at 11:06 AM ET
Vaxcyte Inc (PCVX) Stock Forecast
Analysts expect Vaxcyte (PCVX) to earn -$7.86 per share in the fiscal year ending Dec 31, 2026. Of 11 analysts, 10 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 91% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 9.1% |
| Buy | 9 | 81.8% |
| Hold | 1 | 9.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$7.86
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$6.62
- EPS consensus, revenue $68.89M
- Next report
- Feb 22, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$7.86 | -$8.62 to -$7.18 | 7 | N/A | N/A | 9 |
| Dec 31, 2027 | -$6.62 | -$9.56 to -$4.52 | 7 | $68.89M | N/A | 9 |
Quarterly Estimates
The EPS consensus rises from -$2.01 for the quarter ending Dec 31, 2026 to -$1.51 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.01 | -$2.70 to -$0.90 | 12 |
| Mar 31, 2027 | -$1.51 | -$2.00 to -$0.97 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 8 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 0 |
| Fiscal year ending Dec 31, 2027 | 4 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$8.20.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$7.86 | -$8.14 | -$8.53 | -$8.20 | -$8.20 | N/A |
| Fiscal year ending Dec 31, 2027 | -$6.62 | -$7.12 | -$7.53 | -$7.22 | -$7.22 | N/A |
| Quarter ending Mar 31, 2027 | -$1.51 | -$1.54 | -$1.32 | -$1.32 | -$1.32 | N/A |
Frequently Asked Questions About PCVX
What is the PCVX stock forecast?
Consensus analyst estimates put Vaxcyte's EPS at -$7.86 for the fiscal year ending Dec 31, 2026. The consensus rating from 11 analysts is Buy.
How do analysts rate PCVX stock?
Of 11 analysts covering Vaxcyte, 1 rates it Strong Buy, 9 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PCVX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$7.86, with estimates from -$8.62 to -$7.18 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$6.62, with estimates from -$9.56 to -$4.52 from 7 analysts.
What revenue do analysts expect from Vaxcyte next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $68.89M.
How many analysts cover PCVX?
11 analysts rate Vaxcyte stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PCVX pages: Overview, Earnings, Forecast, Financials, Competitors